Xbrane Biopharma AB Stock

Equities

XBRANE

SE0007789409

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:29:57 2024-05-03 am EDT 5-day change 1st Jan Change
0.202 SEK -1.70% Intraday chart for Xbrane Biopharma AB -5.39% -97.98%
Sales 2024 * 344M 31.77M Sales 2025 * 680M 62.9M Capitalization 309M 28.57M
Net income 2024 * -186M -17.2M Net income 2025 * 104M 9.62M EV / Sales 2024 * 0.82 x
Net cash position 2024 * 28.17M 2.6M Net Debt 2025 * 116M 10.7M EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
-1.5 x
P/E ratio 2025 *
4.22 x
Employees 93
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.26%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Xbrane Biopharma AB

1 day-1.70%
1 week-5.39%
Current month-6.70%
1 month-29.37%
3 months-86.75%
6 months-99.15%
Current year-97.98%
More quotes
1 week
0.20
Extreme 0.199
0.22
1 month
0.19
Extreme 0.1862
0.43
Current year
0.19
Extreme 0.1862
10.84
1 year
0.19
Extreme 0.1862
92.00
3 years
0.19
Extreme 0.1862
180.40
5 years
0.19
Extreme 0.1862
180.40
10 years
0.19
Extreme 0.1862
180.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 14-12-31
Director of Finance/CFO 63 21-01-10
Chief Tech/Sci/R&D Officer 42 17-10-08
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 70 14-12-31
Director/Board Member 53 19-12-31
More insiders
Date Price Change Volume
24-05-03 0.202 -1.70% 12,159,090
24-05-02 0.2055 -5.08% 8,340,380
24-04-30 0.2165 +4.09% 5,244,928
24-04-29 0.208 -2.58% 12,043,920
24-04-26 0.2135 -1.39% 11,591,000

Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT

More quotes
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.202 SEK
Average target price
0.625 SEK
Spread / Average Target
+209.41%
Consensus
  1. Stock Market
  2. Equities
  3. XBRANE Stock